Macmillan Digital Science, a technology business for researchers, which is part of Macmillan Publishers, has helped 1DegreeBio, an independent review website for antibodies and life science products, raise a series B round.
Philip Armstrong, chief executive of Jovian Capital Corporation, and 1DegreeBio senior management also participated in the round.
Digital Science’s other portfolio companies include SureChem, Labtiva, BioData, BioRAFT, figshare and Symplectic.
1DegreeBio has increased its user base from 23,000 to more than 75,000 users, and increased its product database from 400,000 products to more than 800,000 since July 2011.
Timo Hannay, managing director, Digital Science, said: "1DegreeBio has proven a tremendously valuable resource to the research community. We are pleased to have them as part of the Digital Science family, and look forward to seeing even more developments in their offering in the year to come."
1DegreeBio launched its Epigenetics Portal on June 4 and will be launching a series of other specialised portals to support specific research areas over the next few months.